Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2013

01.07.2013 | Preclinical Study

Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast

verfasst von: Aram S. A. van Brussel, Arthur Adams, Jeroen F. Vermeulen, Sabrina Oliveira, Elsken van der Wall, Willem P. Th. M. Mali, Paul. J. van Diest, Paul M. P. van Bergen en Henegouwen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Ductal carcinoma in situ (DCIS) of the breast is difficult to remove completely during surgery as it is not palpable and can therefore require re-excision. Real-time visualization of DCIS using near-infrared fluorescent probes could help the surgeon during surgery as well as the pathologist post-operatively to distinguish the tumor from healthy tissue. As hypoxia-induced necrosis is a common phenomenon in DCIS, we investigated the molecular imaging of DCIS using a fluorescent antibody targeting a hypoxia marker, carbonic anhydrase IX (CAIX), in a preclinical mouse model. A monoclonal antibody against human CAIX was fluorescently labeled with the near-infrared dye IRDye800CW and characterized in vitro. An in vivo study was performed in SCID/Beige mice that were orthotopically transplanted with human breast cancer cells mimicking human DCIS (MCF10DCIS) and MCF10DCIS stably expressing CAIX. A clinically approved fluorescence imaging system was used to monitor probe uptake and to determine tumor-to-normal tissue ratios (TNR). Mean in vivo TNR of CAIX-transduced (CAIX+) tumors was 7.5 ± 0.5. Mean in vivo TNR of DCIS tumors with hypoxic areas reached a plateau level at 48 h after injection of 2.1 ± 0.1 (mean ± SEM) compared to 1.7 ± 0.1 in DCIS without hypoxic areas. Mean intra-operative TNR of DCIS tumors with necrotic regions was higher than that of DCIS tumors without necrotic regions 96 h after injection—2.9 ± 0.1 and 1.5 ± 0.1, respectively—while the TNR of CAIX+ tumors was 11.2 ± 1.0. Specific tumor uptake of MabCAIX-IRDye800CW was confirmed by a biodistribution assay, and immunofluorescence imaging on tumor sections showed specific uptake in hypoxic tumor regions, with higher contrast than conventional chromagen-based immunohistochemistry. Molecular fluorescence imaging with MabCAIX-IRDye800CW can be successfully used to detect hypoxic DCIS before and during surgery to facilitate radical resection. Furthermore, it allows for sensitive CAIX-specific immunofluorescence microscopy of tumor sections, thereby introducing the concept of molecular fluorescence pathology.
Literatur
2.
Zurück zum Zitat Cutuli B, Lemanski C, Le Blanc-Onfroy M, de Lafontan B, Cohen-Solal-Le-Nir C, Fondrinier E, Mignotte H, Giard S, Charra-Brunaud C, Auvray H, Gonzague-Casabianca L, Quetin P, Fay R (2013) Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases. Cancer Radiother 17(3):196–201. doi:10.1016/j.canrad.2013.01.011 PubMedCrossRef Cutuli B, Lemanski C, Le Blanc-Onfroy M, de Lafontan B, Cohen-Solal-Le-Nir C, Fondrinier E, Mignotte H, Giard S, Charra-Brunaud C, Auvray H, Gonzague-Casabianca L, Quetin P, Fay R (2013) Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases. Cancer Radiother 17(3):196–201. doi:10.​1016/​j.​canrad.​2013.​01.​011 PubMedCrossRef
3.
Zurück zum Zitat Lee LA, Silverstein MJ, Chung CT, Macdonald H, Sanghavi P, Epstein M, Holmes DR, Silberman H, Ye W, Lagios MD (2006) Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in situ of the breast. Am J Surg 192(4):416–419. doi:10.1016/j.amjsurg.2006.06.005 PubMedCrossRef Lee LA, Silverstein MJ, Chung CT, Macdonald H, Sanghavi P, Epstein M, Holmes DR, Silberman H, Ye W, Lagios MD (2006) Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in situ of the breast. Am J Surg 192(4):416–419. doi:10.​1016/​j.​amjsurg.​2006.​06.​005 PubMedCrossRef
4.
Zurück zum Zitat Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL (2010) Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:121–129. doi:10.1093/jncimonographs/lgq034 CrossRef Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL (2010) Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:121–129. doi:10.​1093/​jncimonographs/​lgq034 CrossRef
5.
Zurück zum Zitat Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O’Donoghue JA, Visser EP, Oyen WJ (2012) Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med 53(1):82–89. doi:10.2967/jnumed.111.094896 PubMedCrossRef Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O’Donoghue JA, Visser EP, Oyen WJ (2012) Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med 53(1):82–89. doi:10.​2967/​jnumed.​111.​094896 PubMedCrossRef
6.
Zurück zum Zitat Vermeulen JF, van Brussel AS, Adams A, Mali WP, van der Wall E, van Diest PJ, Derksen PW (2013) Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study. Mol Imaging Biol 15(3):290–298. doi:10.1007/s11307-012-0605-8 PubMedCrossRef Vermeulen JF, van Brussel AS, Adams A, Mali WP, van der Wall E, van Diest PJ, Derksen PW (2013) Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study. Mol Imaging Biol 15(3):290–298. doi:10.​1007/​s11307-012-0605-8 PubMedCrossRef
7.
Zurück zum Zitat Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52(11):1778–1785. doi:10.2967/jnumed.111.092833 PubMedCrossRef Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 52(11):1778–1785. doi:10.​2967/​jnumed.​111.​092833 PubMedCrossRef
8.
Zurück zum Zitat Day KE, Beck LN, Heath CH, Huang CC, Zinn KR, Rosenthal EL (2013) Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma. Cancer Biol Ther 14(3):271–277. doi:10.4161/cbt.23300 PubMedCrossRef Day KE, Beck LN, Heath CH, Huang CC, Zinn KR, Rosenthal EL (2013) Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma. Cancer Biol Ther 14(3):271–277. doi:10.​4161/​cbt.​23300 PubMedCrossRef
9.
Zurück zum Zitat Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W (2012) Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2(1):1–13PubMed Zhang Y, Hong H, Engle JW, Yang Y, Barnhart TE, Cai W (2012) Positron emission tomography and near-infrared fluorescence imaging of vascular endothelial growth factor with dual-labeled bevacizumab. Am J Nucl Med Mol Imaging 2(1):1–13PubMed
10.
Zurück zum Zitat Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93(4):309–314PubMedCrossRef Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93(4):309–314PubMedCrossRef
11.
Zurück zum Zitat Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, van der Wall E (2005) Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 27(1):43–49PubMed Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, van der Wall E (2005) Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 27(1):43–49PubMed
12.
Zurück zum Zitat Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA (2008) Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 8(1):60–67PubMedCrossRef Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA (2008) Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 8(1):60–67PubMedCrossRef
14.
Zurück zum Zitat Jans J, van Dijk JH, van Schelven S, van der Groep P, Willems SH, Jonges TN, van Diest PJ, Bosch JL (2010) Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 75(4):786–792. doi:10.1016/j.urology.2009.08.024 PubMedCrossRef Jans J, van Dijk JH, van Schelven S, van der Groep P, Willems SH, Jonges TN, van Diest PJ, Bosch JL (2010) Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 75(4):786–792. doi:10.​1016/​j.​urology.​2009.​08.​024 PubMedCrossRef
16.
Zurück zum Zitat Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158(3):1011–1019. doi:10.1016/S0002-9440(10)64048-5 PubMedCrossRef Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158(3):1011–1019. doi:10.​1016/​S0002-9440(10)64048-5 PubMedCrossRef
18.
Zurück zum Zitat Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97(6):1573–1581. doi:10.1002/cncr.11246 PubMedCrossRef Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97(6):1573–1581. doi:10.​1002/​cncr.​11246 PubMedCrossRef
19.
Zurück zum Zitat Wang Z, Shi Q, Gu Y, Shen Y, Sun M, Deng M, Zhang H, Fang J, Zhang S, Xie F (2011) Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1alpha in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 207(8):505–513. doi:10.1016/j.prp.2011.06.009 PubMedCrossRef Wang Z, Shi Q, Gu Y, Shen Y, Sun M, Deng M, Zhang H, Fang J, Zhang S, Xie F (2011) Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1alpha in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 207(8):505–513. doi:10.​1016/​j.​prp.​2011.​06.​009 PubMedCrossRef
20.
Zurück zum Zitat van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E (2013) HIF-1alpha overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS ONE 8(2):e56055. doi:10.1371/journal.pone.0056055 PubMedCrossRef van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E (2013) HIF-1alpha overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS ONE 8(2):e56055. doi:10.​1371/​journal.​pone.​0056055 PubMedCrossRef
23.
Zurück zum Zitat Ahlskog JK, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley RB, Neri D (2009) Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 101(4):645–657. doi:10.1038/sj.bjc.6605200 PubMedCrossRef Ahlskog JK, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley RB, Neri D (2009) Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 101(4):645–657. doi:10.​1038/​sj.​bjc.​6605200 PubMedCrossRef
24.
Zurück zum Zitat Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8(4):304–310. doi:10.1016/S1470-2045(07)70044-X PubMedCrossRef Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8(4):304–310. doi:10.​1016/​S1470-2045(07)70044-X PubMedCrossRef
25.
Zurück zum Zitat Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM (2012) Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging 11(1):33–46PubMed Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM (2012) Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging 11(1):33–46PubMed
27.
Zurück zum Zitat Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29(1):121–126. doi:10.1007/s00345-010-0570-2 PubMedCrossRef Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29(1):121–126. doi:10.​1007/​s00345-010-0570-2 PubMedCrossRef
28.
Zurück zum Zitat Schackmann RC, van Amersfoort M, Haarhuis JH, Vlug EJ, Halim VA, Roodhart JM, Vermaat JS, Voest EE, van der Groep P, van Diest PJ, Jonkers J, Derksen PW (2011) Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 121(8):3176–3188. doi:10.1172/JCI41695 PubMedCrossRef Schackmann RC, van Amersfoort M, Haarhuis JH, Vlug EJ, Halim VA, Roodhart JM, Vermaat JS, Voest EE, van der Groep P, van Diest PJ, Jonkers J, Derksen PW (2011) Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 121(8):3176–3188. doi:10.​1172/​JCI41695 PubMedCrossRef
29.
Zurück zum Zitat Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D (2009) An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 11(5):R66. doi:10.1186/bcr2358 PubMedCrossRef Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D (2009) An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 11(5):R66. doi:10.​1186/​bcr2358 PubMedCrossRef
30.
Zurück zum Zitat MacAusland SG, Hepel JT, Chong FK, Galper SL, Gass JS, Ruthazer R, Wazer DE (2007) An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110(12):2648–2653. doi:10.1002/cncr.23089 PubMedCrossRef MacAusland SG, Hepel JT, Chong FK, Galper SL, Gass JS, Ruthazer R, Wazer DE (2007) An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 110(12):2648–2653. doi:10.​1002/​cncr.​23089 PubMedCrossRef
32.
Zurück zum Zitat Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, Hong D, Capaldi A, Geuna M, Piacibello W, Aglietta M (2003) Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol 74(4):593–601. doi:10.1189/jlb.0203068 PubMedCrossRef Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, Hong D, Capaldi A, Geuna M, Piacibello W, Aglietta M (2003) Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol 74(4):593–601. doi:10.​1189/​jlb.​0203068 PubMedCrossRef
33.
Zurück zum Zitat Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC Jr, Raleigh JA (1998) Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71(2):270–277. doi:10.1006/gyno.1998.5163 PubMedCrossRef Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC Jr, Raleigh JA (1998) Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71(2):270–277. doi:10.​1006/​gyno.​1998.​5163 PubMedCrossRef
34.
Zurück zum Zitat Picchio M, Beck R, Haubner R, Seidl S, Machulla HJ, Johnson TD, Wester HJ, Reischl G, Schwaiger M, Piert M (2008) Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med 49(4):597–605. doi:10.2967/jnumed.107.046870 PubMedCrossRef Picchio M, Beck R, Haubner R, Seidl S, Machulla HJ, Johnson TD, Wester HJ, Reischl G, Schwaiger M, Piert M (2008) Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med 49(4):597–605. doi:10.​2967/​jnumed.​107.​046870 PubMedCrossRef
35.
Zurück zum Zitat Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV (2001) [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54(1):73–80PubMedCrossRef Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV (2001) [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54(1):73–80PubMedCrossRef
36.
Zurück zum Zitat Okuda K, Okabe Y, Kadonosono T, Ueno T, Youssif BG, Kizaka-Kondoh S, Nagasawa H (2012) 2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for in vivo imaging of tumor hypoxia. Bioconjug Chem 23(3):324–329. doi:10.1021/bc2004704 PubMedCrossRef Okuda K, Okabe Y, Kadonosono T, Ueno T, Youssif BG, Kizaka-Kondoh S, Nagasawa H (2012) 2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for in vivo imaging of tumor hypoxia. Bioconjug Chem 23(3):324–329. doi:10.​1021/​bc2004704 PubMedCrossRef
37.
Zurück zum Zitat Tafreshi NK, Bui MM, Bishop K, Lloyd MC, Enkemann SA, Lopez AS, Abrahams D, Carter BW, Vagner J, Grobmyer SR, Gillies RJ, Morse DL (2012) Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clinical Cancer Res 18(1):207–219. doi:10.1158/1078-0432.CCR-11-0238 CrossRef Tafreshi NK, Bui MM, Bishop K, Lloyd MC, Enkemann SA, Lopez AS, Abrahams D, Carter BW, Vagner J, Grobmyer SR, Gillies RJ, Morse DL (2012) Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probes. Clinical Cancer Res 18(1):207–219. doi:10.​1158/​1078-0432.​CCR-11-0238 CrossRef
38.
Zurück zum Zitat Bao B, Groves K, Zhang J, Handy E, Kennedy P, Cuneo G, Supuran CT, Yared W, Rajopadhye M, Peterson JD (2012) In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PLoS ONE 7(11):e50860. doi:10.1371/journal.pone.0050860 PubMedCrossRef Bao B, Groves K, Zhang J, Handy E, Kennedy P, Cuneo G, Supuran CT, Yared W, Rajopadhye M, Peterson JD (2012) In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PLoS ONE 7(11):e50860. doi:10.​1371/​journal.​pone.​0050860 PubMedCrossRef
39.
Zurück zum Zitat Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H (2005) HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5:84. doi:10.1186/1471-2407-5-84 PubMedCrossRef Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H (2005) HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5:84. doi:10.​1186/​1471-2407-5-84 PubMedCrossRef
40.
Zurück zum Zitat Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP (2007) Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 29(3):219–227PubMed Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP (2007) Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol 29(3):219–227PubMed
41.
Zurück zum Zitat Seeber LM, Horree N, van der Groep P, van der Wall E, Verheijen RH, van Diest PJ (2010) Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer 10:307. doi:10.1186/1471-2407-10-307 PubMedCrossRef Seeber LM, Horree N, van der Groep P, van der Wall E, Verheijen RH, van Diest PJ (2010) Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer 10:307. doi:10.​1186/​1471-2407-10-307 PubMedCrossRef
Metadaten
Titel
Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast
verfasst von
Aram S. A. van Brussel
Arthur Adams
Jeroen F. Vermeulen
Sabrina Oliveira
Elsken van der Wall
Willem P. Th. M. Mali
Paul. J. van Diest
Paul M. P. van Bergen en Henegouwen
Publikationsdatum
01.07.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2635-6

Weitere Artikel der Ausgabe 2/2013

Breast Cancer Research and Treatment 2/2013 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.